Tharimmune (NASDAQ:THAR) Upgraded at Wall Street Zen

Tharimmune (NASDAQ:THAR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.00.

Tharimmune Price Performance

Shares of Tharimmune stock opened at $3.09 on Friday. The firm has a market cap of $23.51 million, a price-to-earnings ratio of -0.51 and a beta of 1.41. Tharimmune has a one year low of $0.95 and a one year high of $9.08. The stock’s 50-day moving average is $3.49 and its 200 day moving average is $2.16.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.06).

Institutional Trading of Tharimmune

A hedge fund recently bought a new position in Tharimmune stock. XTX Topco Ltd purchased a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,911 shares of the company’s stock, valued at approximately $25,000. XTX Topco Ltd owned approximately 0.31% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is currently owned by institutional investors.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).